Cite
HARVARD Citation
Griffiths, C. et al. (2022). Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. Journal of dermatological treatment. pp. 848-856. [Online].